Navigation Links
Generic Drug Decision Disastrous to Patient Safety
Date:6/23/2011

WASHINGTON, June 23, 2011 /PRNewswire-USNewswire/ -- Today's U.S. Supreme Court decision in Pliva v. Mensing is a disastrous outcome for patient safety, giving generic drug companies legal immunity when they ignore harmful side-effects of the drugs they manufacture and profit from.  This decision eliminates any incentive for generic manufacturers to ensure their drug is safe and adequately warn consumers of their drugs' potential dangers.

This decision also means that brand-name manufacturers will be held to a different yet safer standard.  The Supreme Court decided in Wyeth v. Levine, brand-name manufacturers are responsible for their warning labels and required to update them at all times.  

"Patients will now be taking generic drugs at their own risk," said American Association for Justice President Gibson Vance. "It is absurd that doctors and patients will have to make medical decisions knowing that only brand-name drug manufacturers – not generics – can be held accountable for their drugs' dangerous side-effects."

Today, 70 percent of all prescription drugs are filled with generic versions, accounting for about 2.6 billion prescriptions every year.  Additionally, the generic drug industry continues to expand – nine of the industry's 10 biggest blockbuster drugs are going off-patent within in the next few years. 

"Congress and the Food and Drug Administration need to quickly address the huge legal disparity between brand-name and generic drugs," said Vance.  "Today's decision sends a dangerous and expensive message to patients: you are safer taking brand-name drugs."

Louis Bograd, Senior Litigation Counsel at the Center for Constitutional Litigation, argued this case on behalf of Mensing, and AAJ also filed an amicus brief.  For more information, visit www.justice.org/courts.  To speak with counsel or parties in Pliva v. Mensing, contact Jennifer.Fuson@justice.org, 202-944-2896.Drugs Expected to Come off Patent in the United States by Year:2011

2012

2014Actos

Plavix

Lexapro

CelebrexCozaar

Seroquel

Singulair

CymbaltaConcerta

Valtrex

Viagra

NexiumEffexor

ZyPrexaRisperdalFlomaxSymbicortImitrexLevaquinLipitorLotrelAs the world's largest trial bar, the American Association for Justice (formerly known as the Association of Trial Lawyers of America) works to make sure people have a fair chance to receive justice through the legal system when they are injured by the negligence or misconduct of others--even when it means taking on the most powerful corporations. Visit http://www.justice.org.


'/>"/>
SOURCE American Association for Justice
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lupin Announces Launch of Generic Levaquin® Tablets
2. FDA Approves First Generic Versions of the Antibiotic Levofloxacin to Treat Certain Infections
3. Watson Confirms Court Decision Rejecting Tevas Motion to Prevent Launch of Generic SEASONIQUE®
4. Perrigo Announces Launch of the Generic Version of Nasacort® AQ
5. HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer
6. Breckenridge Announces Approval of Generic Activella® 0.5mg/0.1mg Tablets
7. Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products
8. Mylan Receives Approval for Generic Version of Aricept® Tablets
9. Mylan Receives Approval for Generic Version of Effexor XR® Capsules
10. Reportlinker Adds Generic Pharmaceuticals Industry - Top 200 Generic Pharmaceuticals Industry (Global)
11. Mylan Launches Generic Version of Roxicodone® Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):